B. Hooshyar Yousefi, B. C. Uzuegbunam, W. Paslawski, G. B. Kotipalli, M. Luster, D. Librizzi, W. Weber, P. Svenningsson, T. Arzberger
{"title":"Selective α-Synuclein PET Radiotracer Development- Characterization","authors":"B. Hooshyar Yousefi, B. C. Uzuegbunam, W. Paslawski, G. B. Kotipalli, M. Luster, D. Librizzi, W. Weber, P. Svenningsson, T. Arzberger","doi":"10.1055/s-0043-1766158","DOIUrl":null,"url":null,"abstract":"Ziel/Aim The deposition of α-synuclein fibrils (α-syn) is a major feature that unites a group of neurodegenerative diseases collectively known as the synucleinopathies. Presently, the in vivo detection of this biomarker is not possible due to lack of suitable radiotracers. Scientists from academics and industry are interested to develop radiotracers for the early diagnosis of α-synucleinopathies. Disarylbisthiazoles (DABTAs) based ligands have been showing high affinity towards α-syn and excellent selectivity over tau and Aβ aggregates. The aim of this work is characterization of the radiotracers within competition binding assays, autoradiography and pharmacokinetics (PK) study to confirm their high binding affinity and optimized pharmacokinetics and utilize them as a promising α-syn PET tracer.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"106 1","pages":"0"},"PeriodicalIF":1.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuklearmedizin-nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1766158","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Ziel/Aim The deposition of α-synuclein fibrils (α-syn) is a major feature that unites a group of neurodegenerative diseases collectively known as the synucleinopathies. Presently, the in vivo detection of this biomarker is not possible due to lack of suitable radiotracers. Scientists from academics and industry are interested to develop radiotracers for the early diagnosis of α-synucleinopathies. Disarylbisthiazoles (DABTAs) based ligands have been showing high affinity towards α-syn and excellent selectivity over tau and Aβ aggregates. The aim of this work is characterization of the radiotracers within competition binding assays, autoradiography and pharmacokinetics (PK) study to confirm their high binding affinity and optimized pharmacokinetics and utilize them as a promising α-syn PET tracer.
期刊介绍：
Als Standes- und Fachorgan (Organ von Deutscher Gesellschaft für Nuklearmedizin (DGN), Österreichischer Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN), Schweizerischer Gesellschaft für Nuklearmedizin (SGNM, SSNM)) von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte Nuklearmedizin/ NuclearMedicine mit Diagnostik und Therapie in der Nuklearmedizin und dem Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen der Diagnose und Therapie dar.
Ausführliche Berichte aus den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab.
Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben.
Nuklearmedizin erscheint regelmäßig mit sechs Ausgaben pro Jahr und richtet sich vor allem an Nuklearmediziner, Radiologen, Strahlentherapeuten, Medizinphysiker und Radiopharmazeuten.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
